Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Calvo E, Sessa C, Harada G, de Miguel M, Kahatt C, Luepke-Estefan XE, Siguero M, Fernandez-Teruel C, Cullell-Young M, Stathis A, Drilon A. Calvo E, et al. Among authors: de miguel m. Invest New Drugs. 2022 Dec;40(6):1263-1273. doi: 10.1007/s10637-022-01281-z. Epub 2022 Aug 10. Invest New Drugs. 2022. PMID: 35947247 Free PMC article. Clinical Trial.
The future of oncology therapeutics.
Mansinho A, Boni V, de Miguel M, Calvo E. Mansinho A, et al. Among authors: de miguel m. Expert Rev Anticancer Ther. 2017 Jul;17(7):563-565. doi: 10.1080/14737140.2017.1331131. Epub 2017 May 22. Expert Rev Anticancer Ther. 2017. PMID: 28504011 No abstract available.
Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M, Calvo E. de Miguel M, et al. Cancer Cell. 2020 Sep 14;38(3):326-333. doi: 10.1016/j.ccell.2020.07.004. Epub 2020 Aug 3. Cancer Cell. 2020. PMID: 32750319 Free article. Review.
T-cell-engaging Therapy for Solid Tumors.
de Miguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E. de Miguel M, et al. Clin Cancer Res. 2021 Mar 15;27(6):1595-1603. doi: 10.1158/1078-0432.CCR-20-2448. Epub 2020 Oct 20. Clin Cancer Res. 2021. PMID: 33082210 Review.
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
Harding JJ, Moreno V, Bang YJ, Hong MH, Patnaik A, Trigo J, Szpurka AM, Yamamoto N, Doi T, Fu S, Calderon B, Velez de Mendizabal N, Calvo E, Yu D, Gandhi L, Liu ZT, Galvao VR, Leow CC, de Miguel MJ. Harding JJ, et al. Among authors: de miguel mj. Clin Cancer Res. 2021 Apr 15;27(8):2168-2178. doi: 10.1158/1078-0432.CCR-20-4405. Epub 2021 Jan 29. Clin Cancer Res. 2021. PMID: 33514524 Clinical Trial.
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME, Forster M, Moreno V, López-Criado MP, Braña I, Flynn M, Doger B, de Miguel M, López-Vilariño JA, Núñez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Olmedo ME, et al. Among authors: de miguel m. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11. Invest New Drugs. 2021. PMID: 33704620 Free PMC article. Clinical Trial.
406 results